UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1474-1
Program Prior Authorization/Notification
Medication Alhemo® (concizumab-mtci)
P&T Approval Date 3/2025
Effective Date 6/1/2025
1. Background:
Alhemo (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric
patients 12 years of age and older with:
• hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors
• hemophilia B (congenital factor IX deficiency) with FIX inhibitors
2. Coverage Criteriaa:
A. Hemophilia A With Inhibitors
1. Initial Authorization
a. Alhemo will be approved based on all of the following criteria:
(1) Diagnosis of hemophilia A
-AND-
(2) Patient is 12 years of age or older
-AND-
(3) Patient has factor VIII inhibitors
-AND-
(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Alhemo will be approved based on the following criterion:
(1) Documentation of positive clinical response to Alhemo therapy
Authorization will be issued for 12 months.
B. Hemophilia B With Inhibitors
© 2025 UnitedHealthcare Services Inc.
1
1. Initial Authorization
a. Alhemo will be approved based on all of the following criteria:
(1) Diagnosis of hemophilia B
-AND-
(2) Patient is 12 years of age or older
-AND-
(3) Patient has factor IX inhibitors
-AND-
(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Alhemo will be approved based on the following criterion:
(1) Documentation of positive clinical response to Alhemo therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Medical Necessity and supply limits may be in place.
4. References:
1. Alhemo® [package insert]. Plainsboro, NJ: Novo Nordisk Inc., December 2024.
Program Prior Authorization/Notification - Hemlibra (emicizumab-kxwh)
Change Control
3/2025 New program.
© 2025 UnitedHealthcare Services Inc.
2